J C Hassel
Overview
Explore the profile of J C Hassel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
750
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Robert C, Long G, Larkin J, Wolchok J, Hassel J, Schadendorf D, et al.
Eur J Cancer
. 2024 Nov;
214:115119.
PMID: 39612757
Purpose: To investigate the predictive value of RECIST response within 3, 6, or 12 months on long-term survival, and explore differences between nivolumab+ipilimumab and nivolumab monotherapy, we analyzed pooled 5-year...
2.
DAngelo S, Lebbe C, Mortier L, Brohl A, Fazio N, Grob J, et al.
ESMO Open
. 2024 May;
9(5):103461.
PMID: 38744102
Background: Results from the JAVELIN Merkel 200 study led to the approval of avelumab [an anti-programmed death-ligand 1 (PD-L1) antibody] for the treatment of metastatic Merkel cell carcinoma (mMCC) in...
3.
Kramer N, Muller G, Zierold S, Rockel M, Frohlich W, Schefzyk M, et al.
J Eur Acad Dermatol Venereol
. 2024 Feb;
38(8):e722-e728.
PMID: 38400651
No abstract available.
4.
Piulats J, Watkins C, Costa-Garcia M, Del Carpio L, Piperno-Neumann S, Rutkowski P, et al.
Ann Oncol
. 2023 Dec;
35(3):317-326.
PMID: 38048850
Background: Tebentafusp demonstrated a superior overall survival (OS) benefit [hazard ratio (HR) 0.51] compared to investigator's choice (82% pembrolizumab) in a randomized, phase III trial (IMCgp100-202; N = 378) in...
5.
Kahler K, Huning S, Nashan D, Meiss F, Rafei-Shamsabadi D, Rissmann H, et al.
J Cancer Res Clin Oncol
. 2023 Jul;
149(13):11705-11718.
PMID: 37405475
Purpose: Adjuvant treatment with immune checkpoint inhibitors like PD1-antibodies (ICI) ± CTLA4-antibodies (cICI) or targeted therapy with BRAF/MEK inhibitors (TT) in high-risk melanoma patients demonstrate a significant improvement in disease-free...
6.
Jordan B, Benesova K, Hassel J, Wick W, Jordan K
ESMO Open
. 2021 Nov;
6(6):100317.
PMID: 34839103
Immune-related neuromuscular adverse events are rare, but potentially life-threatening side-effects of immune checkpoint inhibitors (ICIs). They usually arise within the first 3 months after initiation of ICIs. Subacute symptom onset...
7.
Hassel J, Livingstone E, Allam J, Behre H, Bojunga J, Klein H, et al.
ESMO Open
. 2021 Aug;
6(5):100248.
PMID: 34438241
Melanoma is one of the most common cancers in adolescents and adults at fertile age, especially in women. With novel and more effective systemic therapies that began to profoundly change...
8.
Gutzmer R, Sibaud V, Hassel J
Ann Oncol
. 2021 Aug;
32(10):1310.
PMID: 34373158
No abstract available.
9.
Gutzmer R, Sibaud V, Hassel J
Ann Oncol
. 2021 Apr;
32(6):696-697.
PMID: 33882330
No abstract available.
10.
Livingstone E, Zaremba A, Horn S, Ugurel S, Casalini B, Schlaak M, et al.
Br J Dermatol
. 2020 Feb;
183(5):928-939.
PMID: 32064597
Background: GNAQ and GNA11 mutant nonuveal melanoma represent a poorly characterized rare subgroup of melanoma with a gene mutation profile similar to uveal melanoma. Objectives: To characterize these tumours in...